These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 33803)

  • 41. Follow up of Graves' patients thyroid stimulating antibody activity during treatment. A prospective study.
    Bakó G; Lenkey A; Szabó T; Karanyi Z; Forizs E; Kálmán K; Szabó J; Varvölgyi C; Leövey A
    Radiobiol Radiother (Berl); 1987; 28(5):600-4. PubMed ID: 2894709
    [No Abstract]   [Full Text] [Related]  

  • 42. Detection and measurement of fat cell-binding immunoglobulins: a new method applicable to the diagnosis and study of Graves' disease.
    Shinozawa T; Villadolid MC; Ingbar SH
    J Clin Endocrinol Metab; 1986 Jan; 62(1):1-9. PubMed ID: 2999173
    [TBL] [Abstract][Full Text] [Related]  

  • 43. On the effect of thyrotropin and immunoglobulins related to Graves' disease on thyrotropin synthesis and secretion.
    Dandona P; El Kabir DJ
    Clin Endocrinol (Oxf); 1978 Oct; 9(4):321-7. PubMed ID: 581481
    [No Abstract]   [Full Text] [Related]  

  • 44. Concentration of long-acting thyroid stimulator (LATS) by subfractionation of gamma G globulin from Graves' disease serum.
    Miyai K; Werner SC
    J Clin Endocrinol Metab; 1966 May; 26(5):504-12. PubMed ID: 5952570
    [No Abstract]   [Full Text] [Related]  

  • 45. Relationship between the long-acting thyroid stimulator and circulating thyroid antibodies in Graves' disease.
    Pinchera A; Liberti P; De Santis R; Grasso L; Martino E; Baschieri L
    J Clin Endocrinol Metab; 1967 Dec; 27(12):1758-60. PubMed ID: 6072765
    [No Abstract]   [Full Text] [Related]  

  • 46. Validation of cytochemical section bioassay for thyroid-stimulating immunoglobulins in treated and untreated Graves' disease.
    Prentice MG; Alaghband-Zadeh J; Wise PH
    J Immunoassay; 1984; 5(3-4):275-90. PubMed ID: 6549396
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Significance of long-acting thyroid stimulator. Reflections on the 1st series of results].
    Tourneur R; Letonturier P; Sénécal P
    Minerva Med; 1974 Mar; 65(19):995-8. PubMed ID: 4406464
    [No Abstract]   [Full Text] [Related]  

  • 48. The interaction of MHC and Gm in liability to autoimmune thyroid disease.
    Nagataki S
    Mol Biol Med; 1986 Feb; 3(1):73-84. PubMed ID: 3007922
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Absence of allotypic variation in the autoantigen for thyroid stimulating autoantibodies.
    Knight A; Adams DD
    Clin Exp Immunol; 1983 May; 52(2):317-24. PubMed ID: 6134598
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The immunologic basis of Graves's disease.
    Volpé R
    N Engl J Med; 1972 Aug; 287(9):463-4. PubMed ID: 5068098
    [No Abstract]   [Full Text] [Related]  

  • 51. Immunological aspects of Graves' disease and importance of thyroid stimulating immunoglobulins.
    Bech K
    Acta Endocrinol Suppl (Copenh); 1983; 254():3-38. PubMed ID: 6191508
    [No Abstract]   [Full Text] [Related]  

  • 52. Human thyroid adenyl cyclase-stimulating activity in immunoglobulin G of patients with Graves' disease.
    Orgiazzi J; Williams DE; Chopra IJ; Solomon DH
    J Clin Endocrinol Metab; 1976 Feb; 42(2):341-54. PubMed ID: 946604
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thyroid xenografts from patients with Graves' disease in severe combined immunodeficient mice and NIH-beige-nude-xid mice.
    Mukuta T; Arreaza G; Nishikawa M; Resetkova E; Jamieson C; Tamai H; Volpé R
    Clin Invest Med; 1997 Feb; 20(1):5-15. PubMed ID: 9013039
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plasma LATS and thyroid antibody level, and the clinical manifestations of Graves' disease.
    Földes J; Takó J; Bános C; Gesztesi E; Varga I
    Acta Med Acad Sci Hung; 1969; 26(3):233-43. PubMed ID: 5395883
    [No Abstract]   [Full Text] [Related]  

  • 55. Neutralization of the long-acting thyroid stimulator by thyroid subcellular fractions.
    Berumen FO; Lobsenz IL; Utiger RD
    J Lab Clin Med; 1967 Oct; 70(4):640-9. PubMed ID: 6072404
    [No Abstract]   [Full Text] [Related]  

  • 56. Letter: L.A.T.S. and Graves' disease.
    Volpé R; Farid NR; Von Westarp C; Row VV
    Lancet; 1974 Oct; 2(7884):843. PubMed ID: 4138250
    [No Abstract]   [Full Text] [Related]  

  • 57. [Thyroid-stimulating antibodies].
    Kandror VI; Ibragim MD
    Probl Endokrinol (Mosk); 1985; 31(4):75-80. PubMed ID: 2864686
    [No Abstract]   [Full Text] [Related]  

  • 58. Letter: Nomenclature of thyroid-stimulating antibodies.
    Adams DD; Dirmikis S; Doniach D; El Kabir DJ; Hall R; Ibbertson HK; Irvine WJ; Kendall-Taylor P; Manley SW; Mehdi SQ; Munro DS; Purves HD; Smith BR; Stewart RD
    Lancet; 1975 May; 1(7917):1201. PubMed ID: 48829
    [No Abstract]   [Full Text] [Related]  

  • 59. Circulating inhibitor of LATS: a bioassay artefact.
    Burke G
    J Clin Endocrinol Metab; 1973 Jun; 36(6):1244-50. PubMed ID: 4740050
    [No Abstract]   [Full Text] [Related]  

  • 60. [Concentration of plasma in hyperthyroid patients for the detection of G immunoglobulins with LATS activity].
    Orgiazzi J; Rousset B; Mornex R
    Ann Endocrinol (Paris); 1972; 33(2):139-47. PubMed ID: 4678454
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.